What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Leukemia, Gastroenterology, Myeloid leukemia and Imatinib mesylate.
His biological study spans a wide range of topics, including Surgery, Immunology and Oncology.
His research in Leukemia intersects with topics in Myeloid, Myelodysplastic syndromes, Philadelphia chromosome and Pharmacology.
His work deals with themes such as Phases of clinical research, Cytarabine, Survival rate, Neutropenia and Myelofibrosis, which intersect with Gastroenterology.
The various areas that he examines in his Myeloid leukemia study include Salvage therapy and Fms-Like Tyrosine Kinase 3.
The subject of his Imatinib mesylate research is within the realm of Imatinib.
His most cited work include:
- Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias (1448 citations)
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 (1271 citations)
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (1219 citations)
What are the main themes of his work throughout his whole career to date?
Jorge E. Cortes spends much of his time researching Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Surgery.
His research ties Immunology and Internal medicine together.
His Oncology research is multidisciplinary, incorporating perspectives in Cancer, Hematopoietic stem cell transplantation, Clinical trial and Newly diagnosed.
The study incorporates disciplines such as Myeloid, Adverse effect, Pharmacology and Bone marrow in addition to Myeloid leukemia.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Cytarabine, Neutropenia, Chemotherapy, Phases of clinical research and Myelofibrosis.
Jorge E. Cortes interconnects Chronic myelogenous leukemia, Tyrosine kinase, Philadelphia chromosome and Tyrosine-kinase inhibitor in the investigation of issues within Imatinib.
He most often published in these fields:
- Internal medicine (68.77%)
- Oncology (31.39%)
- Myeloid leukemia (31.04%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (68.77%)
- Oncology (31.39%)
- Myeloid leukemia (31.04%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Oncology, Myeloid leukemia, In patient and Cytarabine.
Jorge E. Cortes usually deals with Internal medicine and limits it to topics linked to Gastroenterology and Bone marrow.
His Oncology study incorporates themes from Hematopoietic stem cell transplantation, Newly diagnosed, Febrile neutropenia and Cancer.
Jorge E. Cortes has researched Myeloid leukemia in several fields, including Tyrosine kinase and Tyrosine-kinase inhibitor.
His Leukemia research integrates issues from Myeloid and Clinical trial.
The Dasatinib study combines topics in areas such as Nilotinib and Imatinib mesylate.
Between 2017 and 2021, his most popular works were:
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia (305 citations)
- Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML (231 citations)
- Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome (185 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of investigation include Internal medicine, Myeloid leukemia, Oncology, Leukemia and Cytarabine.
His research combines Gastroenterology and Internal medicine.
His Myeloid leukemia study combines topics from a wide range of disciplines, such as Hematology, Refractory and Tyrosine-kinase inhibitor.
His research integrates issues of Hematopoietic stem cell transplantation, Clinical trial, Venetoclax, Febrile neutropenia and Blinatumomab in his study of Oncology.
His Leukemia research includes elements of Cancer, Survival rate, Mutation, Decitabine and Survival analysis.
His studies in Cytarabine integrate themes in fields like Daunorubicin, Regimen and Transplantation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
